


Furafylline

Cat. No.:	HY-107204		
CAS No.:	80288-49-9		
Molecular Formula:	C ₁₂ H ₁₂ N ₄ O ₃		
Molecular Weight:	260.25		
Target:	Cytochrome P450		
Pathway:	Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 12.5 mg/mL (48.03 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
			1 mM	3.8425 mL	19.2123 mL	38.4246 mL
			5 mM	0.7685 mL	3.8425 mL	7.6849 mL
			10 mM	0.3842 mL	1.9212 mL	3.8425 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.17 mg/mL (8.34 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.17 mg/mL (8.34 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	Furafylline is a potent and selective inhibitor of human cytochrome P450IA2 with an IC ₅₀ of 0.07 μM.
IC ₅₀ & Target	IC ₅₀ : 0.07 μM (human cytochrome P450IA2) ^[1]
In Vivo	<p>Furafylline is a potent and selective inhibitor of human cytochrome P450IA2 with an IC₅₀ of 0.07 μM in kinase experiment. Furafylline is a methylxanthine derivative that is introduced as a long-acting replacement for theophylline in the treatment of asthma. Administration of Furafylline is associated with an elevation in plasma levels of caffeine, due to inhibition of caffeine oxidation, a reaction catalysed by one or more hydrocarbon-inducible isoenzymes of P450. Furafylline has either very little or no effect on human monooxygenase activities catalysed by other isoenzymes of P450, including P4501ID1, P4501IC, P450IIIA^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

CUSTOMER VALIDATION

- Naunyn Schmiedebergs Arch Pharmacol. 2023 Feb 27.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Sesardic D, et al. Furfaylline is a potent and selective inhibitor of cytochrome P450IA2 in man. Br J Clin Pharmacol. 1990 Jun;29(6):651-63.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA